Skip to main content
. 2015 Jul 1;60(1):9–15. doi: 10.1590/2359-3997000000078

Table 4. Individual characteristics of patients with DTC that developed NSSPM.

  Gender DTC histological subtype Age at DTC diagnosis (years) Age at NSSPM diagnosis (years) RAI-131 Cumulative I-131 activity (mCi) Time period from RAI-131 and NSSPM (years) NSSPM Histological type
1 F FTC 36.4 61.1 Yes 100 4.3 Adenocarcinoma#
2 F PTC 42.2 69.2 Yes 100 16.8 Skin (melanoma)
3 M FTC 68.2 78.5 Yes 620 9.7 Prostate
4 F FTC 68.1 69.8 Yes 150 1.1 Breast
5 F PTC 52.5 61.5 Yes 300 8.9 Uterus
6 F PTC 59.3 68.3 Yes 100 8.1 Skin (BCC)
7 F PTC 64.8 75.0 Yes 350 9.8 Breast
8 F PTC 48.6 53.9 Yes 350 4.0 Gastric
9 F PTC 48.0 52.4 Yes 100 3.7 Uterus
10 F PTC 76.5 79.3 Yes 150 2.6 Breast
11 F PTC 59.1 72.3 Yes 900 12.8 Breast
12 M FTC 53.3 55.3 Yes 150 2.0 Skin (SCC)
13 F PTC 42.1 46.5 Yes 100 3.8 Lungs
14 F PTC 39.4 41.9 No - - Breast
15 F FTC 43.3 56.7 No - - Skin (BCC)
16 M PTC 49.1 54.1 No - - Prostate
17 F PTC 39.3 44.0 No - - Breast

DTC: differentiated thyroid carcinoma; NSSPM: non-synchronous second primary malignancy; RAI-131= I131 radioactive iodine treatment; F: female; M: male; PTC: papillary thyroid carcinoma; FTC: follicular thyroid carcinoma; BCC: basal cell cancer; SCC: squamous cell cancer. # Adenocarcinoma indicates glandular epithelium neoplasm from unknown site other than thyroid cancer, excluded by immunohistochemical study.